Q-omics provides the consensus-scored INTS6L profile across patient tissues and cancer cell-line models. INTS6L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, INTS6L is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, INTS6L RNA expression shows 19,700 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where INTS6L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INTS6L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INTS6L survival associations across molecular data types. INTS6L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INTS6L RNA expression–survival associations across cancer types. High INTS6L expression shows unfavorable associations in KIRC and KIRP, but favorable associations in HNSC, CESC, BLCA and CHOL. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for INTS6L RNA expression.
This table summarizes INTS6L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for INTS6L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INTS6L shows lower tumor expression in KICH, BRCA and PRAD and higher tumor expression in KIRC, HNSC and CHOL. The KIRC box plot shows higher INTS6L RNA expression in tumor versus normal tissue (log2 FC = +1.051, t-test p < 0.001).
This table shows molecular features associated with INTS6L in patient tissues and cancer cell lines. In patient samples, INTS6L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, INTS6L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
